Paritaprevir
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Paritaprevir
Description:
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) [1][2][3][4].Product Name Alternative:
ABT-450; VeruprevirUNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
HCV; HCV Protease; SARS-CoVType:
Reference compoundRelated Pathways:
Anti-infection; Metabolic Enzyme/ProteaseApplications:
COVID-19-anti-virusField of Research:
InfectionAssay Protocol:
https://www.medchemexpress.com/Paritaprevir.htmlPurity:
99.87Solubility:
DMSO : ≥ 125 mg/mL|H2O : < 0.1 mg/mLSmiles:
O=C ([C@]1 (NC ([C@@]2 ([H]) N3C[C@H] (OC4=C (C=CC=C5) C5=C6C (C=CC=C6) =N4) C2) =O) [C@H] (/C=C\CCCCC[C@H] (NC (C7=NC=C (C) N=C7) =O) C3=O) C1) NS (=O) (C8CC8) =OMolecular Formula:
C40H43N7O7SMolecular Weight:
765.88Precautions:
H302, H315, H319, H335References & Citations:
[1]Smith MA, et al. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015 Nov 13;9:6083-94.|[2]Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01229-15.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|[4]Menon RM, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015 Jul;63 (1) :20-9.Shipping Conditions:
Room TemperatureStorage Conditions:
4°C (Powder, sealed storage, away from moisture and light)Scientific Category:
Reference compound1Clinical Information:
LaunchedCAS Number:
1216941-48-8
